Gold prices edge higher on raised Fed rate cut hopes
Yale Catriona, Chief Development Officer at Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a series of stock transactions involving the company’s common stock. On January 27, 2025, Catriona sold shares totaling approximately $3.01 million. The selling price ranged from $55.156 to $57.024 per share, notably close to the company’s 52-week high of $58.40. The stock has shown remarkable strength, delivering over 156% returns in the past year, with a current market capitalization of $3.86 billion. According to InvestingPro analysis, analysts maintain a strong buy consensus with price targets ranging from $42 to $96.
In addition to these sales, Catriona exercised options to acquire shares at prices ranging from $0.615 to $21.09 per share, amounting to a total acquisition value of $561,806. These transactions were conducted as part of a pre-established Rule 10b5-1 trading plan, which was adopted on May 24, 2024. Following these transactions, Catriona holds 95,648 shares of Akero Therapeutics. The company maintains a strong financial health score of "GOOD" according to InvestingPro metrics, with 15 additional investment insights available to subscribers.
In other recent news, Akero Therapeutics has been the subject of multiple analyst upgrades following encouraging results from the Phase 2b SYMMETRY study. Jefferies has increased Akero’s price target to $75, emphasizing the company’s potential in the NASH market. Similarly, Canaccord Genuity raised its price target to $73, following the release of positive 96-week SYMMETRY data on Akero’s leading therapeutic candidate, efruxifermin (EFX).
Citi analysts also revised their price target upward to $80, citing promising EFX data for patients with compensated cirrhosis. H.C. Wainwright increased its target for Akero to $72, reflecting the potential value of EFX for patients with MASH and F2/F3 fibrosis. Morgan Stanley (NYSE:MS) showed confidence in Akero by raising the company’s price target to $96, following impressive outcomes from the SYMMETRY study.
These upgrades come after Akero reported preliminary topline results from the SYMMETRY study, which showed a statistically significant reversal in fibrosis for patients treated with EFX. These are recent developments in Akero Therapeutics’ ongoing efforts to advance treatments in their respective fields.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.